vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Vroom, Inc. (VRM). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $235.9M, roughly 1.4× Vroom, Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs -59.8%, a 73.0% gap on every dollar of revenue. On growth, Vroom, Inc. posted the faster year-over-year revenue change (12.9% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-108.8M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -49.5%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Vroom, Inc. is a parent company of United Auto Credit Corporation (UACC) and CarStory. Previously, Vroom was a used car retailer and e-commerce company that let consumers buy, sell, and finance cars online. Vroom ceased e-commerce automotive sales operations on January 22, 2024.
HAE vs VRM — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $235.9M |
| Net Profit | $44.7M | $-141.1M |
| Gross Margin | 59.7% | 12.3% |
| Operating Margin | 19.9% | -11.5% |
| Net Margin | 13.2% | -59.8% |
| Revenue YoY | -2.7% | 12.9% |
| Net Profit YoY | 19.3% | -669.8% |
| EPS (diluted) | $0.95 | $-80.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | — | ||
| Q3 25 | $327.3M | — | ||
| Q2 25 | $321.4M | — | ||
| Q1 25 | $330.6M | — | ||
| Q4 24 | $348.5M | — | ||
| Q3 24 | $345.5M | — | ||
| Q2 24 | $336.2M | — | ||
| Q4 23 | $336.3M | $235.9M |
| Q4 25 | $44.7M | — | ||
| Q3 25 | $38.7M | — | ||
| Q2 25 | $34.0M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $33.8M | — | ||
| Q2 24 | $38.4M | — | ||
| Q4 23 | $31.2M | $-141.1M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q4 23 | 52.9% | 12.3% |
| Q4 25 | 19.9% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 21.6% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 11.8% | — | ||
| Q4 23 | 13.7% | -11.5% |
| Q4 25 | 13.2% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 17.5% | — | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 11.4% | — | ||
| Q4 23 | 9.3% | -59.8% |
| Q4 25 | $0.95 | — | ||
| Q3 25 | $0.81 | — | ||
| Q2 25 | $0.70 | — | ||
| Q1 25 | $1.17 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.66 | — | ||
| Q2 24 | $0.74 | — | ||
| Q4 23 | $0.61 | $-80.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $135.6M |
| Total DebtLower is stronger | $1.2B | $454.2M |
| Stockholders' EquityBook value | $911.5M | $127.7M |
| Total Assets | $2.5B | $1.5B |
| Debt / EquityLower = less leverage | 1.34× | 3.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — | ||
| Q4 23 | $194.0M | $135.6M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $454.2M |
| Q4 25 | $911.5M | — | ||
| Q3 25 | $849.2M | — | ||
| Q2 25 | $882.3M | — | ||
| Q1 25 | $820.8M | — | ||
| Q4 24 | $906.9M | — | ||
| Q3 24 | $878.9M | — | ||
| Q2 24 | $905.4M | — | ||
| Q4 23 | $943.3M | $127.7M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q4 23 | $2.2B | $1.5B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | 3.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-108.1M |
| Free Cash FlowOCF − Capex | $87.2M | $-108.8M |
| FCF MarginFCF / Revenue | 25.7% | -46.1% |
| Capex IntensityCapex / Revenue | 1.9% | 0.3% |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-536.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | — | ||
| Q3 25 | $111.3M | — | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $116.6M | — | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $48.8M | — | ||
| Q2 24 | $-27.4M | — | ||
| Q4 23 | $-540.0K | $-108.1M |
| Q4 25 | $87.2M | — | ||
| Q3 25 | $106.3M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $39.4M | — | ||
| Q2 24 | $-33.1M | — | ||
| Q4 23 | $-15.2M | $-108.8M |
| Q4 25 | 25.7% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -9.8% | — | ||
| Q4 23 | -4.5% | -46.1% |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q4 23 | 4.4% | 0.3% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q4 23 | -0.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
VRM
Segment breakdown not available.
